Growth in children on kidney replacement therapy: a review of data from patient registries by BONTHUIS, Marjolein et al.
EDUCATIONAL REVIEW
Growth in children on kidney replacement therapy: a review of data
from patient registries
Marjolein Bonthuis1 & Jérôme Harambat2 & Kitty J. Jager1 & Enrico Vidal3
Received: 1 April 2021 /Accepted: 27 April 2021
# The Author(s) 2021
Abstract
Growth retardation is a major complication in children with chronic kidney disease (CKD) and on kidney replacement therapy
(KRT). Conversely, better growth in childhood CKD is associated with an improvement in several hard morbidity–mortality
endpoints. Data from pediatric international registries has demonstrated that improvements in the overall conservative manage-
ment of CKD, the search for optimal dialysis, and advances in immunosuppression and kidney transplant techniques have led to a
significant improvement of final height over time. Infancy still remains a critical period for adequate linear growth, and the loss of
stature during the first years of life influences final height. Preliminary new original data from the European Society for Paediatric
Nephrology/European Renal Association-European Dialysis and Transplant Association (ESPN/ERA-EDTA) Registry confirm
an association between the final height and the height attained at 2 years in children on KRT.
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Introduction
Chronic kidney disease (CKD) has wide-ranging and long-
term consequences for children and their families, including
growth retardation, which is a marker of disease severity.
Growth retardation may occur at any stage of CKD and is
related to multiple modifiable and non-modifiable risk factors
[1]. The latter include age at onset of CKD, abnormal birth
history, kidney disease etiology, genetic factors (i.e., parental
height), and use of required medications (i.e., steroids for
immune-mediated diseases or after kidney transplantation)
[2]. Primary pathogenic mechanisms can involve prenatal/
perinatal factors, nutrition and caloric intake, mineral and
bone metabolism disorders, hormonal influences from the pi-
tuitary gland, and other metabolic abnormalities (collectively
termed as uremic milieu), including metabolic acidosis, ane-
mia, and inflammation.
Clinical and experimental evidence demonstrates that per-
turbations in the growth hormone (GH)-insulin-like growth
factor-1 (IGF-1) axis are responsible for many important com-
plications seen in CKD, such as growth retardation and pro-
tein energy wasting, as well as disease progression [1, 3, 4].
These alterations include changes in the 24-h levels of spon-
taneous GH release, reduced GH receptor density in target
organs, and disturbed cascade of intracellular signaling events
(post-receptor defect). This results in a functional IGF-1 defi-
ciency, in which free bioactive levels are further reduced by an
increased binding capacity due to excess of IGF-binding pro-
teins. Growth hormone insensitivity in CKD lays the basis for
recombinant human growth hormone therapy (rhGH), an ef-
fective and well-tolerated intervention to improve growth.
Adequate physical growth is a paramount outcome in chil-
dren with CKD. Better growth in childhood CKD is associat-
ed with an improvement in several hard clinical endpoints
[5–9]. Moreover, adequate stature during pediatric CKD in-
fluences patient and parental perspectives [10, 11], and satis-
faction with adult life [12].
Given the overall impact of growth on health-related qual-
ity of life (HRQoL), evaluation, prevention, and management
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of growth failure are essential in children with CKD. Trends in
physical growth are commonly evaluated in registry-based
research and might indicate a change in the epidemiology of
childhood CKD.
In this review, we aim to give an overview of the statural
growth in children receiving chronic kidney replacement ther-
apy (KRT), integrating data from international registries.
Moreover, prompted by a suggestion from Professor Lesley
Rees during a recent scientific meeting, we used data from the
European Registry for Children on KRT (European Society
for Paediatric Nephrology/European Renal Association-
European Dialysis and Transplant Association (ESPN/ERA-
EDTA) Registry) to evaluate the hypothesis that height
attained during infancy in stage 5 chronic kidney disease
(CKD 5) patients is a predictor of final height.
Association of growth retardation
with outcomes
Growth failure after pediatric KRT has been associated with
poor social and health outcomes. In pre-dialysis populations,
HRQoL was lower among children with short stature [11, 13],
and height gains and rhGH use were associated with improved
parent-reported HRQoL [11]. In a recent analysis from the
Kids with CKD study, among 375 children from Australia
and New Zealand with CKD, on dialysis and after kidney
transplantation (KT), quality of life scores were significantly
lower among dialysis patients, and short stature was associat-
ed with poorer quality of life [14]. Children with short stature
more often have emotional and behavioral problems, includ-
ing anxiety, low self-esteem, social immaturity, learning dis-
abilities, and poor academic achievement [15, 16]. One-third
of adult patients with childhood onset CKD 5were dissatisfied
with their body height [17], and a Dutch cohort study found
that patients starting KRT < 15 years of age who attained a
short adult height were less likely to have children after 30
years on KRT [18]. Furthermore, short stature has been asso-
ciated with lower levels of employment and lower marital
status [12]. However, a more recent study on adult social
and professional outcomes after pediatric KT did not find such
associations, and the authors concluded that height seemed to
be sufficiently improved and is no longer a major determinant
in social and professional outcomes after pediatric CKD 5
[19].
Short stature could also affect kidney graft function. In the
CKiD cohort, patients with a short stature prior to transplan-
tation had a 40% shorter time to reaching an eGFR < 45 ml/
min/1.73 m2 after KT compared to children with a normal
stature, although this association was partly explained by
socio-economic status, disease severity, and mid-parental
height [20].
Finally, short stature in pediatric CKD 5 has also been
associated with increased hospitalization [7] and mortality
[7, 9, 21], mainly due to a higher risk of infectious complica-
tions. Although not causally associated, the elevated mortality
risk in CKD 5 patients with short stature may in part reflect
poor nutritional status and severity of illness. Still, the associ-
ations of growth failure with poor patient outcomes indicate
the importance of obtaining a normal adult height for the pa-
tients’ daily functioning. Table 1 summarizes the associations
of height in children on KRT and various outcome measures
reported by several international pediatric KRT registries.
Improvement in growth after KRT
By the 1970s, the availability of KRT allowed many children
with CKD 5 to survive into adulthood. Other clinical out-
comes than patient survival then became critical, and special
focus was put on growth in children with CKD in the follow-
ing decades. Franke et al. have reported the gains made in
growth and maturation in pediatric CKD 5 patients, particu-
larly in Germany [23]. In the mid-1980s, the mean height
standard deviation score (SDS) of 732 European children on
KRT included in the EDTA registry was < −3. Mean height
SDS markedly improved over time to −1.80 in 384 German
children receiving KRT in the 1998–2009 era [23]. The final
height also improved significantly over the past decades [6,
24]. In the USA, final height SDS for transplanted patients
having reached 19 years (n = 2569) improved from −1.93 in
1987–1991 to −0.89 in the 2007–2013 period [24]. Similarly,
final height SDS increased from −2.06 SDS in European chil-
dren on KRT who reached adulthood in 1990–1995 to −1.33
SDS in those reaching adulthood in 2006–2011 [6]. However,
the ESPN/ERA-EDTA Registry showed no secular trends in
growth post transplantation in European children between
1990 and 2012 according to the period of KT, suggesting that
the improvement of final height over time is most likely ex-
plained by better pre-CKD 5 care [25].
Dialysis
In pediatric patients, dialysis should be considered as a tran-
sition period before receiving a KT and should aim at attaining
adequate body weights for receiving a KT. In CKD patients,
growth failure is an indication for dialysis initiation, and good
growth and development during dialysis are the principal in-
dices of dialysis adequacy. “Adequate dialysis” usually refers
to a minimum dose below which a clinically unacceptable rate
of negative outcomes occurs, and it is defined by a fixed
threshold or a number. Given the strong association between
growth, clinical outcomes, and quality of life in children
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receiving KRT, “adequate growth” becomes a marker of “op-
timal dialysis” in this setting.
In the 2011 annual dialysis report from the NAPRTCS
registry [26], the 5022 patients had on average a height SDS
of −1.60 at dialysis initiation. Height deficits were worse for
males, younger patients, and those treated with hemodialysis
(HD) as compared with peritoneal dialysis (PD). Patients were
also stratified according to a baseline height deficit: height
SDS < or > than the third percentile of the normal population.
Children with a height SDS > 3rd percentile at baseline expe-
rienced a decrease in height SDS during the dialysis course,
whereas the height SDS of children with a height SDS < 3rd
percentile at baseline improved slightly from −3.21 SDS to
−2.90 SDS by 24 months. In all age categories, children treat-
edwith HD experienced a worse median change from baseline
during the dialysis course, as compared with PD.
Residual kidney function
Residual kidney function (RKF) exerts a significant influence
on growth in children on dialysis and is a better predictor of
longitudinal growth than dialytic clearance. In 24 patients
treated with PD for a minimum of 1 year [27], the mean height
SDS changed from −1.58 at baseline to −1.78 after 1 year of
treatment. Catch-up growth was observed in 9 patients (37%),
7 of whom had RKF. In contrast, only 5 of 15 patients (33%)
with a negative delta height SDS had RKF. Similarly, an anal-
ysis of 12-month follow-up data in 214 pre- and early-pubertal
patients in the International Pediatric Peritoneal Dialysis
Network (IPPN) database showed that preserved residual di-
uresis was significantly associated with the odds of increasing
height SDS in children treated with PD (odds ratio: 3.25; 95%
confidence interval: 1.66–6.31) [28].
Peritoneal dialysis
There are few papers describing growth outcomes in infants
on chronic PD, and the results from these studies are contro-
versial. In the cohort studied by Ledermann et al. [29], mean
height SDS at the start of PD was −1.8, and it increased to
−1.1 at 1 year and to −0.8 at 2 years. The majority of the 20
children in this case series were affected by CAKUT and had
preserved RKF. None of the infants received rhGH therapy,
while 18 were given enteral feeding via a nasogastric tube or
percutaneous gastrostomy. In a sample of 84 infants who
started PD at < 1 year of age, the Italian Registry of Chronic
Dialysis showed that mean height SDS was −1.65 at the start
of chronic PD, −1.82 after 12 months, and −1.53 after 24
months [30]. The longer follow-up in this study allowed dem-
onstration of a catch-up growth in half of the treated infants,
and SDS values at 2 years of follow-up were similar to those at
PD initiation. Infants with catch-up growth were not different
from those without, with regard to several biochemical param-
eters, RKF, distribution of comorbidities, and proportion of
children on rhGH treatment. Interestingly, a positive relation-
ship was found between height SDS and both fill volume and
treatment duration after 1 year of PD. Moreover, children with
better growth rates suffered from a significantly lower number
of peritonitis episodes.
Among 153 children from the IPPN Registry who initiated
PD during infancy, the use of biocompatible PD fluids low in
toxic glucose degradation products was consistently
Table 1 Associations between height and different outcome measures: results from international registries




USRDS [5] Increased risk of hospitalization in case of growth failure: 1.8 hospitalizations/patient year (py) in
severe growth failure, 1.74 hospitalizations/py in moderate growth failure, and 1.2
hospitalizations/py for normal growth subjects over 5 years of follow-up. After adjustment,
patients with severe (HR: 1.12, 95% CI: 1.03–1.22) and moderate (HR: 1.26, 95% CI:
1.17–1.36) growth failure had higher hospitalization rates than those with normal growth
NAPRTCS [7] Patients with short stature (height SDS < −2.5 SDS) had significantly more hospital days per
month than patients with height ≥ −2.5 SDS (median 0.73 compared with 0.44, p < 0.001)
Mortality USRDS [9] Risk of death was higher in children with short (< 3rd percentile) (HR: 1.49, 95% CI: 1.33–1.66)
and tall (> 97th percentile) (HR: 1.32, 95% CI: 1.03–1.69) stature at KRT initiation.
NAPRTCS [7] Children initiating dialysis with height SDS < −2.5 were more likely to die than patients with
height in the normal range (HR: 2.07, 95% CI: 1.53–2.79)
Final height NAPRTCS [22] Incidence of retarded final height SDS (<−1.88) was increased in patients with low height SDS at
transplantation (OR: 0.39, p = 0.001)
ESPN/ERA-EDTA [6] Height SDS at start of KRTwas positively associated with final height SDS. Adjusted final height
SDS was 0.37 (95% CI: 0.32–0.41) higher per 1 SDS increase in height SDS at KRT
ESPN/ERA-EDTA
(Unpublished data, 2021)
Height SDS at 2 years seemed positively associated with final height SDS (ß = 0.17, p = 0.05)
(Fig. 2)
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associated with better body growth [31]. The association
prevailed even after correction for nutritional status and re-
gion, and was quantitatively stronger than the effect of
gastrostomy feeding.
These findings suggest that the management of growth
failure in children on PD can be optimized using a maximum
dialytic and nutritional approach and by examining all suitable
strategies for preserving diuresis, reducing peritoneal mem-
brane inflammation, and preventing peritonitis. Dialysis pre-
scription should not be based on the worsening of biochemical
parameters but instead should reflect a timely tailoring to body
size, RKF, and metabolic needs.
Hemodialysis
In children on chronic HD, despite reaching an adequate dial-
ysis dose based on urea kinetic modeling, many children do
not show improvement of appetite, weight gain, or statural
growth. With conventional HD, significant dietary and fluid
restrictions are needed to prevent interdialytic weight gain
during the “off dialysis” days. However, implementing these
restrictions becomes challenging, especially in the pediatric
age group. Clinical signs of underdialysis indicate that the
prescription should be optimized. HD intensification relies
on modification of factors such as duration, frequency, time,
and modality (HD versus hemodiafiltration (HDF)). In a pilot
study by Fischbach et al. [32], five oligoanuric dialysis pa-
tients were converted from standard HDF (4 h, three times/
week) to daily online HDF (3 h, six times/week). After 6
months, the only prepubertal child included showed a signif-
icant catch-up growth, resulting in a height SDS gain of 1.5
over 24 months. De Camargo et al. performed an observation-
al study on 24 children with CKD 5 undergoing daily HD
[33]. The authors found that the intensified prescription fa-
vored a 0.5 SDS height gain in one-third of patients without
rhGH treatment as compared with 8% in a control group of 26
children on a concurrent conventional HD regimen. In a large
multi-center observational study comparing outcomes of con-
ventional HD versus post-dilution online HDF in children
[34], a significant increase in height SDS over 1 year of treat-
ment was found in patients on convective therapy, whereas
height SDS remained stable in conventional HD. Convective
therapies might achieve higher clearance of middle molecules,
including IGF-1 binding proteins that contribute to functional
IGF deficiency and relative rhGH insensitivity.
Kidney transplantation
Growth after KT is mainly affected by the degree of pre-
transplantation height deficit, age at KT, graft function, and
steroid exposure.
Pre-KRT growth
Growth determinants during the pre-KRT period may include
age at diagnosis of CKD, nutritional intake, primary kidney
disease, tubular impairment, CKD–mineral bone disorder
(CKD–MBD), hormonal disorders, and pre-transplantation
use of rhGH and steroids. Two periods are at a particular risk
of impaired growth velocity: infancy and puberty. Height ve-
locity generally decreases once GFR is below 25 ml/min/1.73
m2 [35]. However, there is evidence that growth impairment
already starts earlier. Indeed, in a CKD analysis of the
NAPRTCS [36] including 1901 patients with CKD stage 2
(GFR of 50–75 ml/min/1.73 m2), 22% had height SDS below
the third percentile (≤ −1.88), and in 2477 children with CKD
stage 3 (GFR of 25–50 ml/min/1.73 m2), 37% had a height
SDS ≤ −1.88. Pre-KT growth impairment may be reduced by
adequate conservative treatment of CKD, including aggres-
sive nutritional support during infancy and early childhood
[37] and treatment with rhGH when indicated [4]. This has
resulted in a significant improvement of pre-KT growth. Data
from the NAPRTCS has shown a remarkable improvement in
height SDS at the time of first KT, which increased from a
mean of −2.4 in 1987 to −1.4 SDS in the 2008 cohort [38].
Age at transplantation
In an ESPN/ERA-EDTA report [25], only infants and pre-
school age children (2 to 5 years) exhibited catch-up growth
post-transplantation (Fig. 1). However catch-up growth oc-
curred mainly during the first 3 years post-transplantation,
and no further improvement was observed thereafter; pre-
school age children who had the largest deficit at the time of
KT (< −2 SDS) exhibited the best growth improvement of 0.6
to 0.8 SDS. Conversely, school age children (6 to 12 years)
and adolescents demonstrated either a limited improvement in
height SDS or even no catch-up growth after KT (Fig. 1).
Similar growth patterns have been reported by the
NAPRTCS [38]. The prepubertal growth deceleration that oc-
curs in the normal population is prolonged after KT, and pu-
berty and bone age are usually delayed [39, 40]. This means
that growth continues for longer than normal, but the height
gain is rarely as much as expected due to loss of height po-
tential [39, 41]. However, some authors have reported that
normal pubertal development and significant catch-up growth
can occur post-KT even in children of pubertal age [42, 43].
Kidney graft function
The effect of a reduced GFR on growth has been known for a
long time [44]. A report from the NAPRTCS assessed final
adult height in recipients transplanted before 11 (girls) or 12
(boys) years, showing that a decreased GFR was an indepen-
dent predictor of reduced final height [22]. Guest et al.
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reported that prepubertal children with a serum creatinine
above 120 μmol/L did not exhibit catch-up growth in the first
year post-KT [45]. Nissel et al. showed that prepubertal catch-
up growth and total pubertal height gain correlated positively
with GFR [39]. Data from the NAPRTCS found that graft
function at 1 and 12 months was associated with growth after
KT; those with a GFR > 90ml/min/1.73 m2 showed improved
height SDS over time [38]. An analysis by eGFR group 12
months after transplantation showed similar results. More re-
cent studies confirmed that graft function is a major determi-
nant of growth after KT [25, 46].
Steroid therapy
Since its introduction more than 60 years ago, it has become
clear that daily and prolonged steroid therapy leads to growth
impairment [47]. Steroid therapy inhibits growth through in-
terferences with the hypothalamus–pituitary/growth hormone/
insulin-like growth factor axis and by its direct effect on bone
formation. It has also been suggested recently that steroids
may decrease longitudinal bone growth in pediatric KT recip-
ients by stimulating the FGF23/FGFR3 signaling pathway
[48]. Pharmacokinetic studies of methylprednisolone in pedi-
atric liver and kidney transplant recipients have demonstrated
that area under serum concentration–time (AUC) rather than
dose was predictive for growth retardation [49, 50]. However,
this correlation between AUC and growth was not unani-
mously found in transplanted children treated with prednisone
or prednisolone [51]. Observational and registry data showed
that steroid exposure is associated with post-transplant height
SDS [25, 52]. There have been studies in the 1990s suggesting
an improvement in growth with daily low or alternate-day
steroid therapy [53, 54]. Steroid withdrawal/avoidance proto-
cols in pediatric KT have been associated with a significant
improvement in height SDS in randomized controlled trials
[55–59]. Prepubertal recipients appeared to have the greatest
benefit which seems to be only very limited in pubertal chil-
dren (Table 2).
Donor type
Pape et al. identified 51 boys who received a KT (30 deceased
donors and 21 living related donors) before the rhGH era and
were followed for at least 5 years [60]. Children who received
a living donor kidney had a significantly greater height SDS
and growth velocity in the first 5 years post-transplantation
than those who received a graft from a deceased donor.
Interestingly, this difference remained significant after adjust-
ment for potential confounders, including graft function. In
the NAPRTCS, living donor kidney recipients had a reduced
height deficit compared to that of deceased donor kidney re-
cipients, and this difference persisted after transplantation, but
the mean adjusted difference was less than 0.3 SDS at 5 years
post-KT [38]. In the ESPN/ERA-EDTA Registry, children
who received a deceased donor kidney were shorter by 0.15
SDS at KT and tended to show a lower catch-up growth post-
transplant than those transplanted with a living donor (+ 0.35
SDS deceased vs. + 0.39 SDS living) [25].
Preemptive kidney transplantation
As dialysis is associated with decreased growth velocity, pre-
emptive KT might optimize growth outcome. Some studies
suggested better height SDS in the first years post-
transplantation in those children who received a preemptive
KT compared to those with dialysis prior to KT [38, 43, 61].
However, this finding was not confirmed by others after ad-
justment for potential confounders [46, 52].
Other factors
A previous NAPRTCS report suggests that race/ethnicity may
also have an impact on growth following transplantation [62].
The change in height SDS was negative in African–American
and Hispanic recipients but positive in Caucasians. However,
ethnicity did not significantly influence growth in multivari-
able analysis.
Birth parameters are important determinants of post-
transplant growth. Children born small for gestational age
(SGA) have significantly poorer growth outcome after KT
compared with non-SGA patients, and their growth is more
likely to be affected by other factors such as use of rhGH in the
pre-transplant period, preemptive KT, and graft function [63].
Finally, several clinical factors like primary kidney disease
(congenital CKD, syndromic disease), anemia, high blood
pressure, metabolic acidosis, or vitamin D deficiency have
variable associations with height SDS and growth post-KT
[25, 46, 52, 64].
Fig. 1 Unadjusted post-transplant growth patterns stratified by age at
kidney transplantation. (Reproduced with minor revision from [25], used
with permission)
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Final height
Despite adequate metabolic and nutritional control, intensified
dialysis regimens, and successful KT, reduced final height
(below the third percentile for age and sex) is present in ap-
proximately 40% of pediatric CKD 5 patients [6, 23]. The
median final height ranges from 145 to 162 cm in females
and from 156 to 174 cm in males [6, 24, 39, 65–67]. In
Europe, the median (IQR) final height after childhood KRT
was −1.65 (−2.64; −0.78) SDS and did not significantly differ
between boys and girls [6], whereas the NAPRTCS registry
reported a median final height of −1.23 SDS [24], a difference
most likely caused by the use of different reference charts
[68].
Important determinants of final height are older age at start
of KRT and KT, cumulative time with a functioning graft, and
greater height SDS at KRT initiation and at KT [6, 39, 65, 69]
(Table 1). Additionally, post-transplant catch-up growth is
restricted to the youngest patients (< 6 years at KT) [25, 69],
and there was no improvement in post-KT height SDS in the
past 25 years in Europe, suggesting that better growth man-
agement in the pre-CKD 5 period is mainly responsible for the
improvement in final height. The pre-existing height deficit
thus seems to be one of the most important factors for the final
height of pediatric CKD 5 patients.
In line with this, we hypothesized that the height of young
children with CKD 5 is already predictive for their final
height. To study the association between height SDS at the
age of 2 years and final height SDS, we used data from the
ESPN/ERA-EDTA Registry. Data was available for 101 pa-
tients from 13 European countries (60%male, 41% congenital
anomalies of the kidney and urinary tract, median age at KRT
(IQR): 1.7; 0.8–2.5 years). Height SDSwas expressed accord-
ing to national or European growth charts [68]. Linear regres-
sion analysis was used, and we adjusted for potential con-
founders. Indeed, after adjusting for age and period at KRT
initiation, sex, and cause of kidney failure, there was a trend
toward an association between height SDS at the age of 2
years and final height SDS (ß = 0.17, p = 0.05) (Fig. 2)
(Unpublished data ESPN/ERA-EDTA Registry, 2021).
However, further research on a larger number of subjects (in-
cluding those not (yet) on KRT) should reveal whether height
at young age is truly predictive of final height in pediatric
CKD 5.
The current final height of CKD 5 patients remains subop-
timal, but strategies such as steroid avoidance/withdrawal im-
munosuppressive regimens in KT recipients [65, 66] and more
regular use of rhGH [70, 71] may improve final height, pos-
sibly even when started during puberty [67]. The expected
increase in final height after being treated with rhGH for a
period of 2–5 years approximates 7 cm [4]. However, unfor-
tunately rhGH prescription seems to be limited and mostly
determined by physician and patient attitudes toward rhGH
therapy rather than by financial hurdles [72].
Role of nutrition
Inadequate nutrition is a common cause of growth failure in
children with CKD. Reduced appetite, gastroesophageal re-
flux, and vomiting are important factors contributing to poor
nutritional intake [73]. Poor appetite has several potential
causes and may result from reduced taste sensation, which
worsens when CKD progresses [74], restrictive diets, medica-
tion use, protein losing states, polydipsia [75], and chronic
inflammation [76].
Growth in early childhood is crucial for final height poten-
tial as one-third of postnatal statural growth occurs during the
first 2 years of life. In infants and young children, poor nutri-
tion is the most important factor contributing to growth im-
pairment [77].






Change in height SDS Controls Change in
height SDS
N Overall Prepubertal Pubertal
Hocker
[55]





2010 30 Late withdrawal 73 0.16 59 −0.04
Sarwal
[57]
2012 36 Avoidance 60 −0.92 −0.43




2013 12 Early withdrawal 14 1.20 1.30 (n = 12) 16 0.60
Webb
[59]
2015 24 Early withdrawal 98 0.57 0.69 (n = 48) −0.04
(n = 50)
98 0.33
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Recently, the Pediatric Renal Nutrition Taskforce pub-
lished clinical practice guidelines for energy and protein re-
quirements for children on CKD [78]. In CKD 2–5D, energy
intake should approximate that of healthy children of similar
chronological age, and in case of suboptimal growth or im-
paired weight gain, energy intake should be adjusted toward
the higher end of the suggested dietary intake. If children are
not able to meet nutritional requirements, tube feeding
should be initiated [78]. Indeed, infants treated with PD in
the IPPN registry who received tube feeding, especially
those on gastrostomy feeding, experienced better preserva-
tion of growth than those on demand feeding: when consid-
ering periods of at least 6 months, the median change in
length SDS was −1.35 (2.63) SDS/year during periods of
demand feeding, −0.72 (1.59) SDS/year during nasogastric
tube feeding, and −0.50 (2.47) SDS/year during periods of
gastrostomy feeding. Length SDS at last observation was
significantly higher in patients with gastrostomy feeding as
compared with those on demand and/or nasogastric tube
feeding, possibly because of reduced vomiting in case of
gastrostomy [31]. Whether tube feeding is associated with
improvement in height SDSbeyond infancy is controversial,
although there are some studies showing catch-up growth
during prepubertal years in CKD patients when tube fed
[37]. A more recent study among 50 children with CKD
and on dialysis not treated with rhGH or KT demonstrated
that enteral tube feeding started after the age of 2 years in
prepubertal children (2–11 years) was associated with an
improved height of +0.21 SDS after 2 years of tube feeding.
However, improvements were restricted to children younger
than 6 years of age and those not treated with dialysis [79].
On the other hand, tube feeding is effective in improving
BMI SDS [31, 79]. Paralleling the global obesity epidemic,
overweight and obesity are also emerging problems in the
pediatric CKD population [80–82]. According to the ESPN/
ERA-EDTA Registry, 20.8% of children < 16 years on KRT
were overweight, and 12.5%were obese [81]. In patients from
the CKiD cohort, the reported median energy and protein
intake among children with CKD was high, and at least half
of the children consumed more energy and protein than rec-
ommended [83, 84].
Energy requirements and enteral feeding regimens should
be adjusted in order to promote optimal growth and to prevent
obesity. Surprisingly, both the IPPN Registry and the ESPN/
ERA-EDTARegistry found an association between short stat-
ure and obesity. These findings may reflect previous attempts
to correct growth failure by energy-dense nutrition, in fact
leading to overweight and obesity with very limited effect
on height gain.
Nevertheless, optimal nutrition is important during all
phases of growth in pediatric CKD, and successful nutritional
management requires involvement of a pediatric renal dieti-
cian [85, 86].
rhGH treatment
Despite supportive measures aimed at correcting complica-
tions of CKD and optimization of KRT, some children with
CKD or KT recipients cannot approach normal height without
rhGH therapy [2]. The GH insensitivity in CKD can be over-
come by the administration of supraphysiological doses of




















Fig. 2 Final height standard
deviation scores (SDS) by height
SDS at the age of 2 years among
101 patients on kidney replace-
ment therapy (KRT) from the
ESPN/ERA-EDTA Registry. The
solid line depicts the linear re-
gression analysis adjusted for age
and period of KRT, sex, and
cause of kidney failure
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rhGH, which results in increased circulating levels of free
IGF-1 and promotes longitudinal growth.
A Cochrane systematic review based on 16 randomized
controlled studies (enrolling 809 children) demonstrated that
12 months of 28 IU/m2/week rhGH in children with all clin-
ical settings of CKD (conservative treatment, on dialysis, or
after KT) resulted in a 3.88 cm increase in height velocity
above that of untreated patients [87]. The frequency of report-
ed side effects of rhGH was generally similar to that of the
control group. Efficacy of rhGH therapy was further con-
firmed by observational data from the NAPRTCS registry
[88]. A total of 787 children with CKD previously rhGH
naïve who received rhGH for 1–4 years were paired with
787 control patients. Treatment with rhGH resulted in a sig-
nificantly greater height velocity SDS, with no significant
impact on the BMI or kidney function.
Recent ly, the ESPN CKD-MBD, Dialysis and
Transplantation Working Groups published detailed clinical
practice recommendations for the use of rhGH in children
with CKD, on dialysis and after KT [4]. According to these
recommendations, all children with stage 3–5D CKD, who
have a well-defined growth failure despite correction of any
amenable complications of CKD, should be candidates for
rhGH therapy, provided they still have a growth potential.
The same indication is provided for KT recipients who have
not experienced any spontaneous catch-up growth 1 year after
transplantation and a steroid-free immunosuppressive regi-
men is not feasible.
Despite supporting evidence, there are still many obstacles
to rhGH therapy in children with CKD 5. Short stature might
be perceived as a cosmetic issue only, and it is easy to ignore.
This “lack of urgency”may result in a delayed prescription of
rhGH therapy, thus reducing treatment efficacy [89].
Treatment costs and reimbursement mechanisms might also
represent a barrier to care, but an ESPN/ERA-EDTA Registry
study found patient and clinician attitudes toward rhGH ther-
apy a bigger issue than costs [72]. Earlier initiation of rhGH in
a small child could be more cost-effective, as it might also
improve the patient body weight, thus allowing early KT
and reducing the time on long-term dialysis.
Infants with CKD from their first months of life often have
difficulty maintaining adequate nutrition, which contributes to
the high prevalence of short stature in this population. The
IPPN Registry analyzed data from 153 children in 18 coun-
tries who commenced chronic PD at < 24 months of age [31].
Inmultivariate analysis, the administration of rhGH for at least
6 months was independently associated with improved length,
even after adjusting for regional factors. Clinical experience
supports the use of rhGH also in infants with CKD. The ESPN
clinical practice guidelines recommend that rhGH therapy
should be considered for infants older than 6 months of age
with CKD 3–5Dwho have a poor growth despite provision of
adequate nutrition [4].
Key summary points
i) Despite treatment advances in pediatric nephrology
care growth retardation remains a major problem in
patients treated for childhood CKD 5.
ii) Most improvements are observed in the pre-CKD 5 pe-
riod, but optimization of dialysis care, steroid avoidance/
withdrawal regimens post-transplantation, and adequate
use of rhGH treatment might be helpful to further de-
crease the burden of growth failure in children on KRT.
iii) According to our preliminary ESPN/ERA-EDTA
Registry analysis, appropriate growth management
during infancy is particularly critical, since patient final
height seems associated with height attained at 2 years
of age.
Multiple choice questions (answers are given after the refer-
ence list)
1. Which statement about growth in pediatric KRT patients
is correct?
a) Improvements in height are mainly obtained during
the pre-CKD 5 period
b) rhGH should not be initiated during infancy
c) Enteral feeding is only advised in dialysis patients
d) Height is not associated with increased hospitaliza-
tion rates
2. Which factors are associated with better growth in pedi-
atric patients treated with dialysis?
a) Biocompatible PD fluids
b) Hemodiafiltration
c) Residual kidney function
d) All of the above
3. Which patient group showed the poorest catch-up growth
after kidney transplantation?
a) Infants
b) Pre-school children (2–5 years)
c) 6–12-year-old patients
d) Adolescents
4. How many pediatric KRT patients roughly grow up as
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5. According to the recent ESPN clinical practice guidelines
on rhGH which patients would be eligible for rhGH
therapy?
a) Dialysis patients with growth failure
b) All children with CKD, on dialysis and after kidney
transplantation with growth failure
c) CKD and dialysis patients with growth failure
d) All children with CKD stage 3–5D with growth fail-
ure once other potentially treatable risk factors for
growth failure are adequately addressed, and there is
growth potential, as well as KT patients without spon-
taneous catch-up growth 1-year post-KT and if
steroid-free immunosuppression is not possible.
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